beta thalassemia

The FDA has accepted for review Bristol Myers Squibb Co's (NYSE: BMY) supplemental application seeking approval for Reblozyl (luspatercept-aamt) in adults with non-transfusion dependent (NTD) beta-thalassemia. The FDA has set a Prescription Drug User Fee Act goal date of...

Imara Inc (NASDAQ: IMRA) has announced data from a pre-specified interim analysis from its Forte Phase 2b trial of tovinontrine (IMR-687) in transfusion-dependent subjects (TDT) with beta-thalassemia. Subjects in the Forte trial were randomized to either a lower dose group (200 mg or 300...

The past few months have been great for small cap bluebird bio Inc (NASDAQ: BLUE), which saw its stock appreciate more than 47.6 percent in the last six months and more than 31 percent in the past month alone, largely helped by the entry of its Gen2 LentiGlobin into the clinic. Benzinga recently...